Publications by authors named "James Yarmolinsky"

South Asians are at higher risk of dyslipidaemia-a modifiable risk factor for cardiovascular diseases (CVDs). We aimed to identify protein targets for dyslipidaemia and CVDs in this population. We used a two-sample Mendelian randomization (MR) approach, supplemented with MR-Egger, weighted median, colocalization, and generalized MR (GMR), to evaluate the effect of 2,800 plasma proteins on high/low/non-high-density lipoprotein cholesterol (HDL-C/LDL-C/nonHDL-C), total cholesterol, and triglycerides.

View Article and Find Full Text PDF

We investigated the effects of 35 inflammatory cytokines on respiratory outcomes, including COVID-19, asthma (atopic and non-atopic), chronic obstructive pulmonary disease (COPD), and pulmonary function indices, using Mendelian randomization and colocalization analyses. The emerging associations were further explored using observational analyses in the UK Biobank. We found an inverse association between genetically predicted macrophage colony stimulating factor (MCSF), soluble intercellular adhesion molecule-1 (sICAM), and soluble vascular cell adhesion molecule-1 with risk of COVID-19 outcomes.

View Article and Find Full Text PDF

Background: Inflammation and immune dysregulation are hypothesized contributors to endometrial carcinogenesis; however, the precise underlying mechanisms remain unclear.

Methods: We measured pre-diagnostically 152 plasma protein biomarkers in 624 endometrial cancer case-control pairs nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Odds ratios (ORs) were estimated using conditional logistic regression, accounting for confounding and multiple comparisons.

View Article and Find Full Text PDF
Article Synopsis
  • - The study assessed how SGLT2 inhibitors impact the risk of prostate cancer, revealing that genetic evidence suggests these inhibitors can significantly lower overall, advanced, and early-onset prostate cancer risk (odds ratio = 0.56).
  • - Analysis of electronic healthcare data showed that SGLT2 inhibitors are linked to a 23% reduced risk of prostate cancer in men with diabetes (hazard ratio = 0.77).
  • - The research concludes that there is substantial evidence supporting the protective effects of SGLT2 inhibitors against prostate cancer, suggesting that further trials are needed to explore their potential for cancer prevention.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the relationship between plasma proteins and stroke risk specifically in South Asian individuals, utilizing genetic data from the UK Biobank and stroke data from the GIGASTROKE consortium.
  • Using advanced statistical methods, researchers identified a potential causal link between the glycoprotein GP6 levels and the likelihood of cardioembolic stroke, showing an odds ratio indicating a significant increase in risk.
  • Findings suggest that GP6 may not have the same effect on stroke risk in European populations, highlighting the importance of genetic ancestry in biomedical research.
View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.9 million new cases in 2020 and a predicted rise to 3.2 million in 2040.

View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer (CRC) is a widely increasing disease linked to high body mass index (BMI), but the exact biological processes connecting these two factors are not well understood.
  • The study employed Mendelian randomization to explore various biomarkers and lifestyle factors potentially mediating the impact of BMI on CRC risk, focusing on elements like inflammation, insulin levels, and physical activity.
  • The findings indicated that higher genetically predicted BMI correlates with increased CRC risk, with evidence suggesting that the relationship might be partly mediated by plasma IGF1, while smoking and physical activity appear to complicate the association rather than mediate it.
View Article and Find Full Text PDF
Article Synopsis
  • * Our research uncovered 40 proteins linked to cancer risks, including PLAUR for breast cancer and CTRB1 for pancreatic cancer, while also noting possible negative side effects like hypertension from altering these proteins.
  • * We found 18 proteins that are associated with cancer risk and linked to existing drugs, plus 15 proteins not yet being studied for clinical use, enhancing our understanding of cancer causes and the implications of targeting these proteins for prevention.
View Article and Find Full Text PDF
Article Synopsis
  • Drug repurposing is a faster and cheaper alternative to traditional drug development, and the study aims to explore the use of immune checkpoint inhibitors for treating more cancers than currently approved.
  • The research will apply two-sample Mendelian randomization to analyze the genetic impact of protein targets related to immune checkpoint inhibitors on survival across seven cancer types, using existing genetic data.
  • No new ethics approval is needed since previously published studies will serve as data sources, and the results will be shared as an open-access publication to promote broader access.
View Article and Find Full Text PDF

Background: Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear.

Methods: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry.

View Article and Find Full Text PDF

Background: Type 2 diabetes is associated with higher risk of several cancer types. However, the biological intermediates driving this relationship are not fully understood. As novel interventions for treating and managing type 2 diabetes become increasingly available, whether they also disrupt the pathways leading to increased cancer risk is currently unknown.

View Article and Find Full Text PDF

Objective: To investigate the association of genetically proxied (using a surrogate biomarker) inhibition of phosphodiesterase 5 (PDE5), an established drug target for erectile dysfunction, with fertility, sexual behaviour, and subjective wellbeing.

Design: Two sample cis-mendelian randomisation study.

Setting: Summary data on genetic associations obtained from the International Consortium for Blood Pressure and UK Biobank.

View Article and Find Full Text PDF

Preclinical and genetic studies suggest that impaired glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling worsens glycemic control. The relationship between GIPR signaling and the risk of cancers influenced by impaired glucose homeostasis is unclear. We examined the association of a variant in , rs1800437 (E354Q), shown to impair long-term GIPR signaling and lower circulating glucose-dependent insulinotropic peptide concentrations, with risk of 6 cancers influenced by impaired glucose homeostasis (breast, colorectal, endometrial, lung, pancreatic, and renal) in up to 235,698 cases and 333,932 controls.

View Article and Find Full Text PDF

Background: Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear.

Methods: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry.

View Article and Find Full Text PDF

Aims/hypothesis: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk.

Methods: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program.

View Article and Find Full Text PDF

Genetic studies of disease progression can be used to identify factors that may influence survival or prognosis, which may differ from factors that influence on disease susceptibility. Studies of disease progression feed directly into therapeutics for disease, whereas studies of incidence inform prevention strategies. However, studies of disease progression are known to be affected by collider (also known as "index event") bias since the disease progression phenotype can only be observed for individuals who have the disease.

View Article and Find Full Text PDF

Background: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically proxied inhibition of LDL-c-lowering drug targets on risk of PrCa.

View Article and Find Full Text PDF

Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate-to-severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibitors) are shared with this novel TYK2 inhibitor. We used a partial loss-of-function variant in TYK2 (rs34536443), previously shown to protect against psoriasis and other autoimmune diseases, to evaluate the potential effect of therapeutic TYK2 inhibition on risk of lung cancer and non-Hodgkin lymphoma.

View Article and Find Full Text PDF
Article Synopsis
  • Endometrial cancer is the most prevalent gynecological cancer in high-income nations and has a significant connection to elevated body mass index (BMI), which is a modifiable risk factor that may influence this cancer more than others.
  • Using Mendelian randomization, researchers examined the causal impact of 14 genetic and molecular risk factors, along with BMI, on the risk of developing endometrial cancer.
  • The analyses revealed a strong link between higher BMI and increased endometrial cancer risk, with additional contributions from hormonal factors like total testosterone, indicating that these molecular traits may mediate the relationship between BMI and the disease.
View Article and Find Full Text PDF

Background: Two-sample Mendelian randomization (2SMR) is an increasingly popular epidemiological method that uses genetic variants as instruments for making causal inferences. Clear reporting of methods employed in such studies is important for evaluating their underlying quality. However, the quality of methodological reporting of 2SMR studies is currently unclear.

View Article and Find Full Text PDF

Dietary factors are assumed to play an important role in cancer risk, apparent in consensus recommendations for cancer prevention that promote nutritional changes. However, the evidence in this field has been generated predominantly through observational studies, which may result in biased effect estimates because of confounding, exposure misclassification, and reverse causality. With major geographical differences and rapid changes in cancer incidence over time, it is crucial to establish which of the observational associations reflect causality and to identify novel risk factors as these may be modified to prevent the onset of cancer and reduce its progression.

View Article and Find Full Text PDF

Background: Epidemiological studies have reported conflicting findings on the potential adverse effects of long-term antihypertensive medication use on cancer risk. Naturally occurring variation in genes encoding antihypertensive drug targets can be used as proxies for these targets to examine the effect of their long-term therapeutic inhibition on disease outcomes.

Methods And Findings: We performed a mendelian randomization analysis to examine the association between genetically proxied inhibition of 3 antihypertensive drug targets and risk of 4 common cancers (breast, colorectal, lung, and prostate).

View Article and Find Full Text PDF

Background: Epidemiological and experimental evidence has linked chronic inflammation to cancer aetiology. It is unclear whether associations for specific inflammatory biomarkers are causal or due to bias. In order to examine whether altered genetically predicted concentration of circulating cytokines are associated with cancer development, we performed a two-sample Mendelian randomisation (MR) analysis.

View Article and Find Full Text PDF